QTTB Stock Quote
| Symbol: | QTTB |
|---|---|
| Quote: | 1.64 |
| Change: | +0.08 |
| Change %: | +5.13% |
| High: | 1.70 |
| Low: | 1.55 |
| Open: | 1.57 |
|---|---|
| Volume: | 174,584 |
| 52 Week: | 1.38-53.79 |
| P/E Ratio: | -0.25 |
| EPS: | -6.58 |
| Market Cap: | 20.00 M |
Company Report
Q32 Bio Inc., a clinical-stage biotechnology firm based in Waltham, Massachusetts, specializes in developing biologic therapeutics aimed at restoring healthy immune balance for patients grappling with autoimmune and inflammatory diseases driven by dysfunctional immune responses in the United States.
At the forefront of its innovative pipeline is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein designed to restore complement regulation. This promising candidate has successfully completed Phase I clinical trials targeting renal and other complement-mediated diseases, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.
In addition to ADX-097, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody that antagonizes the interleukin-7 receptor alpha. This novel therapy is currently in Phase II clinical trials for treating atopic dermatitis and alopecia areata, focusing on re-regulating adaptive immune responses by blocking interleukin-7 and thymic stromal lymphopoietin signaling pathways. Formerly known as AdMIRx Inc., Q32 Bio rebranded in April 2020 to reflect its expanded mission and dedication to pioneering transformative treatments in the biopharmaceutical landscape.
QTTB EPS Chart
QTTB Revenue Chart
QTTB Profile
| Exchange: | NASDAQ |
|---|---|
| Beta: | -0.016254745 |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Employees: | 42 |
| IPO Date: | Mar 28, 2018 |
QTTB News
WALTHAM, Mass. , April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designa... 3 days ago |
-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass. , April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Compan... 17 days ago |
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 25 days ago |
-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Advancing bempikibart in patients with AA, with SIGNAL-AA... 1 months ago |
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) -- -- Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 2... 1 months ago |
Analyst Ratings